We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




AI-Enhanced ECGs Can Improve Diagnosis and Treatment of Obstructive Hypertrophic Cardiomyopathy

By HospiMedica International staff writers
Posted on 09 Mar 2022

Using artificial intelligence (AI) in electrocardiogram (ECG) analysis can improve diagnosis and treatment of hypertrophic cardiomyopathy (HCM), according to findings of a new study pointing to the potential benefits for remote monitoring of the condition. More...

The study by researchers at the University of California San Francisco (UCSF, San Francisco, CA, USA) found that AI-ECG may help identify HCM in its earliest stages and monitor important disease-related changes over time. The team demonstrated that AI analysis of ECGs can not only accurately predict the diagnosis of HCM, but also that AI-ECG correlates longitudinally with cardiac pressures and lab measurements related to HCM. The study showed that AI analysis can capture far more information from ECGs related to obstructive HCM pathophysiology than is currently gained by manual ECG interpretation and was the first study to show that AI analysis of ECGs can potentially be used to monitor disease-related physiologic and hemodynamic measurements.

The researchers applied two separate AI-ECG algorithms to pre-treatment and on-treatment ECGs from the phase-2 PIONEER- OLE clinical trial (a clinical trial for treatment with the HCM drug Mavacamten in adults with symptomatic obstructive HCM). After showing that both algorithms accurately detected HCM in clinical trial data without additional training, they then showed that AI-ECG HCM scores correlated longitudinally with disease status as measured by decreases over time in left ventricular outflow tract gradients and natriuretic peptide (NT-proBNP) levels in these patients.

The longitudinal associations of the AI-ECG HCM score were significant and likely reflected changes in the raw ECG waveform that were detectable by AI-ECGs and correlated with HCM disease pathophysiology and severity. AI-ECG’s potential is broadened by the fact that ECGs can now be measured remotely via smartphone-enabled electrodes and may permit remote assessment of disease progression as well as drug treatment response. According to the researchers, future studies are needed to determine whether AI-ECGs can track disease status and be used as a guide for drug measurement to enhance safety.

Related Links:
University of California San Francisco 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Dual-Screen Medical Display
C822W
New
Captivator EMR Device
Captivator Endoscopic Mucosal Resection Device
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2025 Globetech Media. All rights reserved.